DOTRONIX INC
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>dotx-ex101_040106.htm
<TEXT>
 <HTML>
<HEAD>
<TITLE>Exhibit 10.1 for Dotronix 8K for 04/11/2006 </TITLE>
</HEAD>
<BODY>


<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt; margin-top: 0pt; margin-bottom: 9pt;">ASSET PURCHASE AGREEMENT</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 10pt;"><B>THIS ASSET
PURCHASE AGREEMENT </B>is made and entered into as of the 11th day of April, 2006 by and
between <B>DOTRONIX, INC.</B>, a Minnesota corporation (&#147;Buyer&#148;) and <B>ACCELERATED DRUG
DELIVERY, LLC</B>, a Wisconsin limited liability company (&#147;Seller&#148;).</P>

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt; margin-top: 10pt; margin-bottom: 10pt;">Recitals</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 10pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller is the owner of three homeopathic products for remediation of cold sores and
canker sores and for smoking cessation.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buyer
desires to purchase from Seller all rights in and to the three homeopathic products.</P>

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt;">Agreement</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">NOW,
THEREFORE, for and in consideration of the foregoing recitals and the terms and
conditions hereinafter set forth, the parties hereto agree as follows:</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">Section 1.
       Purchase of Acquired Assets.  Seller hereby sells to Buyer, and Buyer hereby
purchases from Seller, all of Seller&#146;s right, title, and interest in and to the
following (collectively the &#147;Acquired Assets&#148;):</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cold sore remedy known as &#147;KR-78&#148; more particularly described in Exhibit A
attached hereto and incorporated herein;</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
canker sore remedy known as &#147;KR-78A&#148; more particularly described in Exhibit B
attached hereto and incorporated herein;</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cigarette smoking cessation aid known as &#147;RM-78&#148; more particularly described in
Exhibit C attached hereto and incorporated herein;</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
improvements, variations, modifications, and new or reformulations of the items listed in
paragraphs (a), (b), and (c) of this Section 1, whether now existing or hereafter
conceived or developed by Seller (the items listed in paragraphs (a), (b), (c), and (d)
of this Section 1 are collectively referred to as the &#147;Products&#148;);</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
trade secrets, formulas, scientific and manufacturing know-how, trade names, descriptive
or marketing material pertaining to any of the Products (including any copyrighted or
copyrightable material), and other intellectual property pertaining to any of the
Products; and</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
memoranda, written reports, test results, clinical studies, computer records and discs,
and other information of or pertaining to the Products.</P>

<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in; margin-bottom: 3pt;">For and in consideration of the sale and transfer of the
Acquired Assets to Buyer, Buyer is issuing and delivering to Seller 492,121 shares of
Buyer&#146;s common stock, par value $0.05 per share (the &#147;Securities&#148;). </P>




<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 3pt; margin-bottom: 0pt;"><FONT FACE="Times New Roman, Times, Serif"> </FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>


<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="Gregs0.50Margin" FSL="Project" -->
<P STYLE="margin-left: .50in; margin-top: 0pt; margin-bottom: 9pt;">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations of
Buyer </B></P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buyer
is a corporation duly organized, validly existing and in good standing under the laws of
the state of Minnesota.  Buyer has the necessary corporate power and authority to
execute, deliver, and perform this Agreement and the transactions contemplated hereby. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of this Agreement and the performance by Buyer and the
consummation of the transactions contemplated hereunder have been duly authorized by the
board of directors of Buyer and no other corporate proceedings on the part of Buyer are
necessary to authorize this Agreement and the transactions contemplated hereunder.  No
consent of any person not a party to this Agreement nor consent of or filing with any
governmental entity is required to be obtained or performed on the part of Buyer to
execute, deliver, and perform its obligations hereunder.  This Agreement constitutes the
legally valid and binding obligation of Buyer enforceable against Buyer in accordance
with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and other similar laws and equitable principles relating to or
limiting creditor&#146;s rights generally. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the execution and the delivery of this Agreement, nor the consummation of the
transactions contemplated hereby (including performance by Buyer), will (i) violate any
constitution, statute, regulation, rule, order, decree, charge, or other restriction of
any governmental entity to which Buyer is subject or any provision of the charter or
bylaws of Buyer or (ii) conflict with, result in a breach of, constitute a default under,
result in the acceleration of, create in any party the right to accelerate, terminate,
modify, or cancel, or require any notice under any agreement, contract, lease, license,
instrument or other arrangement to which Buyer is a party or by which it is bound or to
which any of its assets is subject (or result in the imposition of any encumbrance upon
any of its assets), except where the violation, conflict, breach, default, acceleration,
termination, modification, cancellation, failure to give notice, or encumbrance could not
reasonably be expected to have a material adverse effect on Buyer or on the ability of
the parties to consummate the transactions contemplated by this Agreement. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buyer
files reports with the Securities and Exchange Commission under Section 13 of the
Securities Exchange Act of 1934, which includes Buyer&#146;s annual report on Form 10-KSB
for fiscal year ended June 30, 2005, quarterly reports on Form 10-QSB for the quarterly
periods ended September 30 and December 31, 2005, and current report on Form 8-K dated
October 19, 2005 (the &#147;SEC Reports&#148;).  None of the SEC Reports, when filed,
contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.50Margin" FSL="Project" -->
<P STYLE="margin-left: .50in; margin-top: 9pt; margin-bottom: 9pt;">Section 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations of
Seller </B></P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller
is a limited liability company duly organized, validly existing and in good standing
under the laws of the state of Wisconsin.  Seller has the necessary power and authority
to execute, deliver, and perform this Agreement and the transactions contemplated hereby. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 4pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of this Agreement and the performance by Seller and the
consummation of the transactions contemplated hereunder have been duly authorized by the
members Seller and no other company proceedings on the part of Seller are necessary to </P>



<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 4pt; margin-bottom: 0pt;"><FONT FACE="Times New Roman, Times, Serif"> 2</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>


<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in; margin-top: 9pt; margin-bottom: 9pt;">authorize this Agreement and the transactions contemplated
hereunder.  No consent of any person not a party to this Agreement nor consent of or
filing with any governmental entity is required to be obtained or performed on the part
of Seller to execute, deliver, and perform its obligations hereunder.  This Agreement
constitutes the legally valid and binding obligation of Seller enforceable against Seller
in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and other similar laws and equitable principles
relating to or limiting creditor&#146;s rights generally. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the execution and the delivery of this Agreement, nor the consummation of the
transactions contemplated hereby (including performance by Seller), will (i) violate any
constitution, statute, regulation, rule, order, decree, charge, or other restriction of
any governmental entity to which Seller is subject or any provision of the articles of
organization or operating agreement of Seller or (ii) conflict with, result in a breach
of, constitute a default under, result in the acceleration of, create in any party the
right to accelerate, terminate, modify, or cancel, or require any notice under any
agreement, contract, lease, license, instrument or other arrangement to which Seller is a
party or by which it is bound or to which any of its assets is subject (or result in the
imposition of any encumbrance upon any of its assets), except where the violation,
conflict, breach, default, acceleration, termination, modification, cancellation, failure
to give notice, or encumbrance could not reasonably be expected to have a material
adverse effect on Seller or on the ability of the parties to consummate the transactions
contemplated by this Agreement. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller
is an &#147;accredited investor&#148; as that term is defined in Rule 501 of Regulation D
adopted under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller
holds all right, title, and interest in and to the Acquired Assets, free and clear of all
liens, claims, interests of others, security interests, or encumbrances, whatsoever, and
the sale and assignment of the Acquired Assets to Buyer under this Agreement will
transfer and convey good and marketable title to the Acquired Assets free and clear of
all liens, claims, interests of others, security interests, or encumbrances, whatsoever. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller
has not received a written notice that any of the Acquired Assets violates or infringes
upon the patent or other intellectual property rights of any person.  To Seller&#146;s
knowledge, each of the Acquired Assets and the manufacture and sale of the Products
included in the Acquired Assets do not violate or infringe the patent or other
intellectual property rights of others in any respect that would, individually or in the
aggregate, reasonably be expected to result in a material adverse effect on the Buyer&#146;s
ownership of the Acquired Assets or the manufacture or distribution of the Products
included in the Acquired Assets and, to the knowledge of the Seller, there is no existing
infringement by another person of any of the patent, trade secret, or other intellectual
property rights pertaining to any of the Acquired Assets. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif'; margin-top: 9pt; margin-bottom: 9pt;">Section 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Restriction
on Transfer</B>. The Securities have not been registered, but are being issued to Seller
by reason of a specific exemption under the Securities Act as well as under certain state
statutes for transactions by an issuer not involving any public offering and that any
disposition of the Securities may, under certain circumstances, be inconsistent with this
exemption. Seller agrees and acknowledges that the Securities must be held and may not be
sold, transferred, or otherwise disposed of for value unless they are subsequently
registered under the Securities Act or an exemption from such registration is available.
The Buyer is under </P>



<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 4pt; margin-bottom: 0pt;"><FONT FACE="Times New Roman, Times, Serif"> 3</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>

<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;">no obligation to register the Securities  under the
Securities  Act. The  certificates  representing  the Securities will bear a legend
restricting  the sale or  disposition  of the  Securities by reference to the
 registration  requirements  of the  Securities  Act, and similar stop transfer notations
will be placed on the shareholder records of Buyer. </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">Section 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Miscellaneous</B>.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be governed by, enforced, and construed under and in accordance with the
laws of the state of Minnesota.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any party institutes any action or suit to enforce this Agreement or to
secure relief from any default hereunder or breach hereof, the non-prevailing party shall
reimburse the prevailing party for all costs, including reasonable attorneys&#146; fees,
incurred in connection therewith and in enforcing or collecting any judgment rendered
therein.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement represents the entire agreement between the Parties relating to the subject
matter hereof.  There are no other courses of dealing, understandings, agreements,
representations, or warranties, written or oral, except as set forth herein.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement may be executed in multiple counterparts, each of which shall be deemed an
original and all of which taken together shall be but a single instrument.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
right and remedy provided herein shall be cumulative with every other right and remedy,
whether conferred herein, at law, or in equity, and may be enforced concurrently
herewith, and no waiver by any party of the performance of any obligation by the other
party shall be construed as a waiver of the same or any other default then, theretofore,
or thereafter occurring or existing.  Due to the unique nature of the relationship
between the parties and the rights conferred hereunder, either party is entitled to seek
and obtain as a remedy for any breach or threatened breach hereof specific performance,
in addition to any other remedy available at law or in equity.</P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
notices, requests, demands, and other communications made in connection with this
Agreement shall be in writing and shall be deemed to have been duly given on the date of
delivery if delivered by hand, or at 5:00 p.m., Central Time on the next business day
following the date sent by facsimile transmission to the telephone numbers identified
below, or two business days following the date deposited with an overnight courier
service with instructions for next business day delivery, or five days after mailing if
mailed by certified or registered mail postage prepaid return receipt requested to the
address listed below:</P>


<!-- MARKER FORMAT-SHEET="Gregs2Column" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0 STYLE="font-size: 12pt; font-family: 'times new roman, times, serif';">
<TR VALIGN=TOP>
<TD WIDTH=40%><P style="margin-left: .5in;">To Buyer at:</P></TD>
<TD WIDTH=60%>Dotronix, Inc.<BR>
11900 Wayzata Blvd., Suite 100<BR>
Hopkins, Minnesota 55305<BR>
Attention: President<BR>
Fax: (952) 546-2529</TD>
</TR>
</TABLE>
<BR>





<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif"> 4</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>

<PAGE>
<PAGE>
<div style="font-size: 12pt;">


<!-- MARKER FORMAT-SHEET="Gregs2Column" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0 STYLE="font-size: 12pt; font-family: 'times new roman, times, serif';">
<TR VALIGN=TOP>
<TD WIDTH=40%><P style="margin-left: .5in;">To Buyer at:</P></TD>
<TD WIDTH=60%>Accelerated Drug Delivery, LLC<BR>
1326 Schofield Ave.<BR>
Schofield, Wisconsin 54476<BR>
Attn:  Chief Executive Officer<BR>
Fax:   (715) 355-3093
</TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;">Either party may change its address for notices by notice
duly given pursuant to this Section 5(f). </P>

<!-- MARKER FORMAT-SHEET="Gregs0.5Indent" FSL="Project" -->
<P STYLE="text-indent: .5in; font-family: 'Times New Roman, Times, Serif';">IN WITNESS
WHEREOF, the parties hereto have executed this Agreement as of the date first above set
forth.</P>

<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;"><B>Dotronix, Inc. </B></P>
<BR>


<!-- MARKER FORMAT-SHEET="Gregs2SignaturePage" FSL="Project" -->
<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="font-family: 'times new roman, times, serif'; font-size: 12pt;">
<TR VALIGN="TOP">
     <TD WIDTH="5%"></TD>
     <TD WIDTH="45%"></TD>
     <TD WIDTH="10%"></TD>
     <TD WIDTH="5%"></TD>
     <TD WIDTH="35%"></TD></TR>
<TR VALIGN="TOP">
     <TD ALIGN=left>By:</TD>
     <TD>&nbsp;&nbsp;&nbsp;&nbsp;/s/</TD>
     <TD>&nbsp;</TD>
     <TD ALIGN=left></TD>
     <TD>&nbsp;</TD></TR>
<TR VALIGN="TOP">
     <TD>&nbsp;</TD>
     <TD STYLE="border-top: solid black 1px;">Duly Authorized Person</TD>
     <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
     <TD>&nbsp;</TD></TR>
</TABLE>
<BR>
<BR><BR>

<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;"><B>Accelerated Drug Delivery, LLC </B></P>
<BR>

<!-- MARKER FORMAT-SHEET="Gregs2SignaturePage" FSL="Project" -->
<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="font-family: 'times new roman, times, serif'; font-size: 12pt;">
<TR VALIGN="TOP">
     <TD WIDTH="5%"></TD>
     <TD WIDTH="45%"></TD>
     <TD WIDTH="10%"></TD>
     <TD WIDTH="5%"></TD>
     <TD WIDTH="35%"></TD></TR>
<TR VALIGN="TOP">
     <TD ALIGN=left>By:</TD>
     <TD>&nbsp;&nbsp;&nbsp;&nbsp;/s/</TD>
     <TD>&nbsp;</TD>
     <TD ALIGN=left></TD>
     <TD>&nbsp;</TD></TR>
<TR VALIGN="TOP">
     <TD>&nbsp;</TD>
     <TD STYLE="border-top: solid black 1px;">Russell Mitchell, Chief Executive Officer</TD>
     <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
     <TD>&nbsp;</TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 1.5in;"><FONT FACE="Times New Roman, Times, Serif"> 5</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>

<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt;">Exhibit A to<BR>
                                                       Asset Purchase Agreement<BR>
                                                         Dated April 11, 2006</P>



<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;">ADD has a non-prescription Canker Sore product that is
being referred to as &#147;KR-78&#148; during its development stage.  &#147;KR-78&#148; is
a      non-prescription, O-T-C product that will take the form of a powder.  The powder
will be contained in a single-use applicator      that will enable the patient to apply a
pre-measured dose of the product precisely to the effected area.  The product will claim
     to reduce the duration and severity of canker sores which can last from 10-14 days.
 The provisional patent for this formulation      is currently in process. </P>




<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 2.5in;"><FONT FACE="Times New Roman, Times, Serif"> 6</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>

<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt;">Exhibit B to<BR>
                                                       Asset Purchase Agreement<BR>
                                                         Dated April 11, 2006</P>


<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;">ADD has a non-prescription Cold Sore product that is being
referred to as &#147;KR-78A&#148; during its development stage.  &#147;KR-78A&#148; is a
     non-prescription, O-T-C product that will take the form of a powder.  The powder
will be contained in a single-use applicator      that will enable the patient to apply a
pre-measured dose of the product precisely to the effected area.  The product will claim
     to reduce the duration and severity of cold sores which can last from 10-14 days.
 The provisional patent for this formulation is      currently in process.  Although the
two aforementioned products are similar their product formulations are not the same and
the      applicators will be different. </P>




<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 2.5in;"><FONT FACE="Times New Roman, Times, Serif"> 7</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>
<DIV STYLE="page-break-after:always"></DIV>

<PAGE>
<PAGE>
<div style="font-size: 12pt;">

<!-- MARKER FORMAT-SHEET="GregsCenter1Bold" FSL="Project" -->
<P ALIGN=CENTER STYLE="font-weight: bold; font-size: 12pt;">Exhibit C to<BR>
                                                       Asset Purchase Agreement<BR>
                                                         Dated April 11, 2006</P>


<!-- MARKER FORMAT-SHEET="Gregs0Margin" FSL="Project" -->
<P STYLE="margin-left: .0in;">ADD has a non-prescription Smoking Cessation product that
is being referred to as &#147;RM-78&#148; during its development stage.  &#147;RM-78&#148;     is
a non-prescription, O-T-C product that will be delivered in a film strip.  The product is
designed as a nicotine replacement      as well as an appetite suppressant that will help
people cope with not being able to smoke and to help people stop smoking. </P>




<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER style="margin-top: 2.5in;"><FONT FACE="Times New Roman, Times, Serif"> 8</FONT></P>
<HR SIZE=5 COLOR=black NOSHADE>
</div>


        </BODY>
        </HTML>

</TEXT>
</DOCUMENT>
